Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.95% -0.35% 13.76M 35200.67
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.08% 115.0% 6.756M Upgrade

Basic Info

Investment Strategy
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Miscellaneous
Broad Category Miscellaneous
Category Name Trading--Leveraged Equity
Category Index S&P 500 TR USD
Prospectus Objective Growth and Income
Fund Owner Firm Name Direxion Funds
Prospectus Benchmark Index
S&P Pharms Select Industry TR USD 300.0%
Broad Asset Class Benchmark Index
^SPXTR 100.0%
Manager Tenure
Paul Brigandi 4.46 yrs
Tony Ng 4.46 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 16
6.756M
-666.64M Category Low
7.930B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of April 30, 2022

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of May 20, 2022. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
-21.15%
19.26%
0.28%
-37.33%
-33.53%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
-0.21%
10.39%
16.56%
-13.84%
57.88%
-28.07%
88.23%
-34.60%
13.93%
-44.17%
40.49%
-24.93%
46.71%
39.79%
-6.02%
-41.40%
--
--
--
-44.94%
47.96%
-7.37%
105.2%
-50.59%
--
--
--
--
--
-24.98%
129.1%
-54.85%
As of May 20, 2022.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-20-22) 0.08%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 17.36
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 19, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 19, 2022

Asset Allocation

As of May 19, 2022.
Type % Net % Long % Short
Cash 51.94% Upgrade Upgrade
Stock 48.06% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Dreyfus Government Secs Cash Mgmt Admin 27.92% 1.00 0.00%
Goldman Sachs FS Treasury Intms Instl 16.75% 1.00 0.00%
Goldman Sachs FS Government Instl 10.71% 1.00 0.00%
Merck & Co Inc 3.37% 93.55 1.59%
Viatris Inc 3.35% 11.80 0.94%
Bristol-Myers Squibb Co 3.16% 76.19 0.30%
Eli Lilly and Co 3.08% 298.85 4.39%
Royalty Pharma PLC Class A 2.98% 39.52 -0.65%
Catalent Inc 2.98% 100.19 0.46%
Johnson & Johnson 2.94% 176.98 1.75%

News

Basic Info

Investment Strategy
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Miscellaneous
Broad Category Miscellaneous
Category Name Trading--Leveraged Equity
Category Index S&P 500 TR USD
Prospectus Objective Growth and Income
Fund Owner Firm Name Direxion Funds
Prospectus Benchmark Index
S&P Pharms Select Industry TR USD 300.0%
Broad Asset Class Benchmark Index
^SPXTR 100.0%
Manager Tenure
Paul Brigandi 4.46 yrs
Tony Ng 4.46 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-20-22) 0.08%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 17.36
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of May 19, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of May 19, 2022

Fund Details

Key Dates
Inception Date 11/15/2017
Last Annual Report Date 10/31/2021
Last Prospectus Date 2/28/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund Yes
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

News

Top Portfolio Holders

0 of 0